Sensus Healthcare, Inc. (NASDAQ:SRTS)

Sensus Healthcare, Inc. (NASDAQ:SRTS) ($6.07; $100.1M market cap) today announced that the company has resumed purchasing shares under its $3 million share repurchase program from August 2023. 

“We are implementing this program now as we view the repurchase of our common stock as a compelling opportunity at current prices,” said Joe Sardano, Chairman and CEO of Sensus Healthcare. “We remain confident in our growth prospects and believe that returning capital to shareholders while maintaining the flexibility to invest in our strategic initiatives best positions us to enhance value for all stakeholders. We completed a similar $3 million repurchase program in 2022.”

This comes on the heels of the stock dropping hard on its Q4 2024 results last week. 

SRTS manufactures and markets non-invasive treatments for skin cancer and keloids to healthcare providers worldwide.

Sensus Healthcare, Inc. (NASDAQ:SRTS) partners with Pompano Veterinary Oncology to pioneer the use of SRT to treat companion animals across South Florida via the use of a mobile van.

“The portability of our SRT system makes it an excellent choice for this mobile companion animal clinic, and we believe that the veterinary channel will be an important one for Sensus over time. Dr. Dominguez has the foresight to provide radiotherapy services to both clinics and homes with the first mobile offering of SRT in the country.”